Compare BRID & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ENTX |
|---|---|---|
| Founded | 1932 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 74.7M |
| IPO Year | 1995 | 2015 |
| Metric | BRID | ENTX |
|---|---|---|
| Price | $7.53 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 2.7K | ★ 104.1K |
| Earning Date | 03-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $174,257,000.00 | $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.22 |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.00 | $1.00 |
| 52 Week High | $9.39 | $3.22 |
| Indicator | BRID | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 34.50 |
| Support Level | $7.42 | $1.00 |
| Resistance Level | $8.07 | $1.61 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 29.25 | 11.87 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.